News

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

ioMicroglia™ is set to accelerate research and drug discovery for neurodegenerative disease.

bit.bio launches the first commercially available human iPSC-derived disease models for Parkinson’s disease that carry the PRKN R2...

bit.bio launches early access to ioSensory Neurons for chronic pain research and therapeutics development for peripheral neuropath...

Further products in CNS portfolio aim to address the translation gap and accelerate research and drug discovery for neurodegenerat...

Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.